Thenox Adverse Reactions

As with all anticoagulants, bleeding is the major adverse effect of enoxaparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables. At the recommended doses, single injections of enoxaparin do not significantly influence platelet aggregation or affect global clotting time (i.e. PT or aPTT).
1%-10%: Central nervous system: confusion (2%), pain.
Gastrointestinal: nausea (3%), diarrhea (2%).
Hematologic & oncologic: Major hemorrhage (<1% to 4%; includes cases of intracranial, retroperitoneal or intraocular hemorrhage; incidence varies with indication/population), thrombocytopenia (moderate 1%; severe 0.1%), anemia (<2%), bruise.
Hepatic: increased serum ALT (6%), increased serum AST (6%).
Local: Hematoma at injection site (9%), irritation at injection site, bruising at injection site, erythema at injection site, pain at injection site.
Renal: Hematuria (≤2%).
Miscellaneous: Fever (5% to 8%).
<1%, post-marketing and/or case report: Alopecia, anaphylaxis, anaphylactoid reaction, eczematous rash (plaques), eosinophilia, epidural hematoma (spinal; after neuraxial anesthesia or spinal puncture; risk may be increased with indwelling epidural catheter or concomitant use of other drugs affecting hemostasis), headache, hepatic injury (hepatocellular and cholestatic), hyperkalemia, hyperlipidemia (very rare), hypersensitivity angiitis, hypersensitivity reaction, hypertriglyceridemia, intracranial hemorrhage (up to 0.8%), osteoporosis (following long-term therapy), pruritic erythematous rash (patches), pruritus, purpura, retroperitoneal hemorrhage, severe anemia (hemorrhagic), shock, skin necrosis, thrombocythemia, thrombocytopenia, thrombosis (prosthetic valve [in pregnant females] or associated with enoxaparin-induced thrombocytopenia; can cause limb ischemia or organ infarction), urticaria, vesiculobullous rash.